Physician profile
Christopher Benhatzel
NPI 1174150809
$15,645.82
in general payments reported to CMS, 2019-2025
16 companies · $6,133 in 2025
The $6,133 reported for 2025 was more than what 95% of Pain Medicine (Physical Medicine & Rehabilitation) providers received nationally (typical 2025 total: $400).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $178 · 2023: $84.10 · 2024: $9,251 · 2025: $6,133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $7,500 · Food and Beverage: $5,380 · Travel and Lodging: $2,588.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $7,500.00 |
| Food and Beverage | $5,379.91 |
| Travel and Lodging | $2,588.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $9,619.22 | 2022-2025 | Synchromedii, Intellis Adaptivestim, Inceptiv |
| Boston Scientific Corporation | $2,967.51 | 2024-2025 | Intracept, General - Pain Management, Wavewriter Alpha Prime 16 |
| Abbott Laboratories | $1,797.98 | 2025 | Proclaim, Eterna |
| Nalu Medical, INC. | $313.34 | 2025 | Nalu Neurostimulation System |
| Curonix LLC | $258.89 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Stryker Corporation | $173.34 | 2024-2025 | Mild Device Kit |
| Averitas Pharma INC. | $154.00 | 2025 | Qutenza |
| Abbvie INC. | $84.10 | 2023 | Botox |
| Globus Medical, INC. | $69.01 | 2025 | Senza |
| Collegium Pharmaceutical, INC. | $46.51 | 2025 | Xtampza, Belbuca |
| Saluda Medical Americas, INC. | $38.19 | 2025 | Evoke |
| Tonix Medicines, INC. | $31.29 | 2025 | Tonmya |
| Si-Bone, INC. | $31.22 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.66 | 2025 | Relistor |
| Lundbeck LLC | $17.40 | 2025 | Vyepti |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik Nro, INC. | $14.16 | 2025 | Prospera |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Benhatzel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.